California Gov. Gavin Newsom has vetoed a bill aimed at limiting the price of insulin, a decision that has sparked outrage among advocates for affordable healthcare. The bill would have enforced a cap of $35 for a 30-day supply of insulin, including deductibles and co-pays, preventing insurance companies from charging excessive amounts for the life-saving drug.
Newsom defended his veto by highlighting the state’s plan to produce its own brand of insulin, named CalRx. According to Newsom, this state-run initiative will provide a 10 milliliter vial of insulin for just $30, making it more affordable for those in need. However, critics argue that this does not address the immediate concerns of diabetic Californians struggling to afford the drug.
One of the bill’s advocates, State Sen. Scott Wiener, expressed disappointment in the governor’s decision. Wiener believes that the veto will result in tens of thousands of Californians with diabetes facing financial hardship in accessing insulin, a hormone vital for their survival. Wiener’s bill aimed to protect vulnerable individuals from skyrocketing prices and ensure they have access to the medicine they require.
The issue of insulin affordability has been a hot topic in California, with the state’s Attorney General Rob Bonta taking legal action against insulin manufacturers earlier this year. Bonta filed a lawsuit accusing these companies of colluding to unlawfully raise the prices of insulin. This legal action reflects the growing recognition of the financial burdens faced by individuals who rely on insulin to manage their diabetes.
In response to public pressure, major insulin makers announced voluntary price reductions for their products in March. However, these reductions may not be sufficient to alleviate the financial strain experienced by many Californians. The recent veto by Gov. Newsom only reinforces concerns regarding affordable access to essential medication, particularly for those with chronic conditions like diabetes.
The vetoed bill’s supporters argue that it is imperative to establish price controls to protect patients from excessive costs. They believe that relying on a state-run production of insulin, while commendable, does not adequately address the core issue of affordability. Urgent action is needed to ensure that everyone has access to the medicine they require to live healthy lives, without imposing unsustainable financial burdens on them.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”